진해제 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 약제 클래스별, 투여 경로별, 연령층별, 최종사용자별, 지역별, 경쟁(2020-2030년)
Antitussive Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Class, By Route of Administration, By Age Group, By End-User, By Region & Competition, 2020-2030F
진해제 세계 시장 규모는 2024년 16억 달러에 달할 것으로 예상되며, 2030년까지 예측 기간 동안 연평균 5.20%의 꾸준한 성장을 보일 것으로 예측됩니다.
세계 진해제 시장은 호흡기 질환의 유병률 증가, 노인 인구 증가, 의료 서비스 접근성 향상으로 인해 지속적인 성장세를 보이고 있습니다. 진해제는 상기도 감염(UTI), 만성폐쇄성폐질환(COPD), 천식, 기관지염, 바이러스 후 증후군과 같은 증상과 관련된 급성 및 만성 기침을 관리하는 데 필수적입니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
16억 달러 |
| 시장 규모 : 2030년 |
21억 7,000만 달러 |
| CAGR : 2025-2030년 |
5.20% |
| 급성장 부문 |
말초성 작용제 |
| 최대 시장 |
북미 |
이 시장은 일반의약품(OTC) 및 처방전 기반 진해제에 대한 소비자의 강력한 수요가 뒷받침하고 있으며, 주요 제약사 및 스타트업이 크게 기여하고 있습니다. 지속적인 연구개발(R&:D) 노력과 의약품 제형의 발전이 경쟁력을 형성하고 제품 혁신을 촉진하고 있습니다.
시장 성장 촉진요인
호흡기 질환 유병률 증가
주요 시장 이슈
규제 장벽과 까다로운 승인
주요 시장 동향
비오피오이드 및 비코데인 제제로의 전환
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 진해제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 약제 클래스별(말초 작용제, 중추 작용제, 기타)
- 투여 경로별(흡입, 경구, 기타)
- 연령별(고령자, 소아, 성인)
- 최종사용자별(홈케어, 병원 및 전문 클리닉, 기타)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 진해제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 진해제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 진해제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 진해제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 진해제 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 진해제 시장 : SWOT 분석
제14장 경쟁 구도
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Bayer AG
- Ipca Laboratories Ltd.
- F. Hoffmann-La Roche Ltd.
- Hikma Pharmaceuticals PLC
- Unique Pharmaceuticals Limited
- Cipla Inc.
- Viatris Inc.
- Aurobindo Pharma
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
Global Antitussive Drugs Market was valued at USD 1.60 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 5.20% through 2030. The Global Antitussive Drugs Market is experiencing sustained growth, primarily driven by the rising prevalence of respiratory diseases, an expanding elderly population, and improved healthcare accessibility. Antitussive drugs, or cough suppressants, are essential in managing acute and chronic coughs linked to conditions such as upper respiratory tract infections (URTIs), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, and post-viral syndromes.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 1.60 Billion |
| Market Size 2030 | USD 2.17 Billion |
| CAGR 2025-2030 | 5.20% |
| Fastest Growing Segment | Peripherally Acting Drugs |
| Largest Market | North America |
This market benefits from strong consumer demand for both over-the-counter (OTC) and prescription-based antitussive medications, with major contributions from leading pharmaceutical corporations and emerging industry players. Ongoing research and development (R&D) efforts, alongside advancements in drug formulations, are shaping competitive dynamics and fostering product innovation.
Key Market Drivers
Rising Prevalence of Respiratory Diseases
The rising prevalence of respiratory diseases is one of the most significant drivers fueling the expansion of the Global Antitussive Drugs Market. With an increasing number of people experiencing respiratory illnesses, the demand for cough suppressants and related medications is witnessing steady growth. Each year, chronic obstructive pulmonary disease (COPD) claims over 3 million lives, yet it remains significantly underprioritized in global healthcare discussions. Affecting more than 380 million people worldwide, COPD is the fourth leading cause of death, imposing a severe economic and healthcare burden. Despite its widespread impact on patients, caregivers, and healthcare systems, the disease continues to receive disproportionately low attention and funding compared to other major noncommunicable diseases. Chronic and acute respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, bronchitis, pneumonia, tuberculosis (TB), and post-viral cough syndromes, are becoming more prevalent worldwide. In 2023, tuberculosis (TB) affected an estimated 10.8 million people globally, including 6.0 million men, 3.6 million women, and 1.3 million children, highlighting its widespread impact across demographics. Present in every country and affecting all age groups, TB continues to pose a significant public health challenge. These conditions often manifest with persistent coughing, requiring effective antitussive (cough suppressant) treatments.
Key Market Challenges
Regulatory Hurdles and Stringent Approvals
One of the primary challenges in the antitussive drugs market is the rigorous regulatory environment governing pharmaceuticals. To ensure safety and efficacy, regulatory agencies such as the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency) impose stringent approval processes for new antitussive drugs.
Developing and bringing a new antitussive drug to market involves extensive clinical trials, data submission, and regulatory reviews. The process is time-consuming and costly, with no guarantee of approval. Companies may face delays, increased development costs, or even the rejection of their drug candidates, impacting market entry.
Key Market Trends
Shift Towards Non-Opioid and Non-Codeine Formulations
One of the prominent trends in the antitussive drugs market is the increasing preference for non-opioid and non-codeine formulations. This shift is primarily driven by concerns related to the addictive potential and side effects associated with opioid-based antitussive drugs.
Regulatory Scrutiny: Regulatory agencies like the FDA have imposed stricter controls and monitoring of opioid-based medications due to their potential for abuse and addiction. This has led to a reduced appetite among healthcare providers to prescribe such drugs. Patient Safety: Patient safety and minimizing the risk of opioid misuse have become paramount concerns. Non-opioid alternatives are seen as safer options for managing coughing, especially in pediatric and vulnerable patient populations.
Advances in pharmaceutical research have led to the development of non-opioid antitussive medications that offer comparable efficacy in suppressing coughing without the risk of opioid-related complications. This has fueled the market demand for non-opioid alternatives.
Key Market Players
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Bayer AG
- Ipca Laboratories Ltd.
- F. Hoffmann-La Roche Ltd.
- Hikma Pharmaceuticals PLC
- Unique Pharmaceuticals Limited
- Cipla Inc.
- Viatris Inc.
- Aurobindo Pharma
Report Scope:
In this report, the Global Antitussive Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Antitussive Drugs Market, By Drug Class:
- Peripherally Acting Drugs
- Centrally Acting Drugs
- Others
Antitussive Drugs Market, By Route of Administration:
Antitussive Drugs Market, By Age Group:
- Geriatric
- Pediatric
- Adult
Antitussive Drugs Market, By End-User:
- Homecare
- Hospitals & Specialty Clinics
- Others
Antitussive Drugs Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Antitussive Drugs Market.
Available Customizations:
Global Antitussive Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Antitussive Drugs Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs, Others)
- 5.2.2. By Route of Administration (Inhalational, Oral, Others)
- 5.2.3. By Age Group (Geriatric, Pediatric, Adult)
- 5.2.4. By End-User (Homecare, Hospitals & Specialty Clinics, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
- 5.3. Market Map
6. North America Antitussive Drugs Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Route of Administration
- 6.2.3. By Age Group
- 6.2.4. By End User
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Antitussive Drugs Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Drug Class
- 6.3.1.2.2. By Route of Administration
- 6.3.1.2.3. By Age Group
- 6.3.1.2.4. By End User
- 6.3.2. Canada Antitussive Drugs Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Drug Class
- 6.3.2.2.2. By Route of Administration
- 6.3.2.2.3. By Age Group
- 6.3.2.2.4. By End User
- 6.3.3. Mexico Antitussive Drugs Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Drug Class
- 6.3.3.2.2. By Route of Administration
- 6.3.3.2.3. By Age Group
- 6.3.3.2.4. By End User
7. Europe Antitussive Drugs Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Route of Administration
- 7.2.3. By Age Group
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Antitussive Drugs Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drug Class
- 7.3.1.2.2. By Route of Administration
- 7.3.1.2.3. By Age Group
- 7.3.1.2.4. By End User
- 7.3.2. United Kingdom Antitussive Drugs Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drug Class
- 7.3.2.2.2. By Route of Administration
- 7.3.2.2.3. By Age Group
- 7.3.2.2.4. By End User
- 7.3.3. Italy Antitussive Drugs Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drug Class
- 7.3.3.2.2. By Route of Administration
- 7.3.3.2.3. By Age Group
- 7.3.3.2.4. By End User
- 7.3.4. France Antitussive Drugs Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Drug Class
- 7.3.4.2.2. By Route of Administration
- 7.3.4.2.3. By Age Group
- 7.3.4.2.4. By End User
- 7.3.5. Spain Antitussive Drugs Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Drug Class
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By Age Group
- 7.3.5.2.4. By End User
8. Asia-Pacific Antitussive Drugs Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Route of Administration
- 8.2.3. By Age Group
- 8.2.4. By End User
- 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Antitussive Drugs Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drug Class
- 8.3.1.2.2. By Route of Administration
- 8.3.1.2.3. By Age Group
- 8.3.1.2.4. By End User
- 8.3.2. India Antitussive Drugs Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drug Class
- 8.3.2.2.2. By Route of Administration
- 8.3.2.2.3. By Age Group
- 8.3.2.2.4. By End User
- 8.3.3. Japan Antitussive Drugs Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drug Class
- 8.3.3.2.2. By Route of Administration
- 8.3.3.2.3. By Age Group
- 8.3.3.2.4. By End User
- 8.3.4. South Korea Antitussive Drugs Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Drug Class
- 8.3.4.2.2. By Route of Administration
- 8.3.4.2.3. By Age Group
- 8.3.4.2.4. By End User
- 8.3.5. Australia Antitussive Drugs Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Drug Class
- 8.3.5.2.2. By Route of Administration
- 8.3.5.2.3. By Age Group
- 8.3.5.2.4. By End User
9. South America Antitussive Drugs Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Route of Administration
- 9.2.3. By Age Group
- 9.2.4. By End User
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Antitussive Drugs Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug Class
- 9.3.1.2.2. By Route of Administration
- 9.3.1.2.3. By Age Group
- 9.3.1.2.4. By End User
- 9.3.2. Argentina Antitussive Drugs Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug Class
- 9.3.2.2.2. By Route of Administration
- 9.3.2.2.3. By Age Group
- 9.3.2.2.4. By End User
- 9.3.3. Colombia Antitussive Drugs Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug Class
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By Age Group
- 9.3.3.2.4. By End User
10. Middle East and Africa Antitussive Drugs Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Drug Class
- 10.2.2. By Route of Administration
- 10.2.3. By Age Group
- 10.2.4. By End User
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Antitussive Drugs Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drug Class
- 10.3.1.2.2. By Route of Administration
- 10.3.1.2.3. By Age Group
- 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Antitussive Drugs Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drug Class
- 10.3.2.2.2. By Route of Administration
- 10.3.2.2.3. By Age Group
- 10.3.2.2.4. By End User
- 10.3.3. UAE Antitussive Drugs Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drug Class
- 10.3.3.2.2. By Route of Administration
- 10.3.3.2.3. By Age Group
- 10.3.3.2.4. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Antitussive Drugs Market: SWOT Analysis
14. Competitive Landscape
- 14.1. Teva Pharmaceutical Industries Ltd.
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. Intas Pharmaceuticals Ltd.
- 14.3. Bayer AG
- 14.4. Ipca Laboratories Ltd.
- 14.5. F. Hoffmann-La Roche Ltd.
- 14.6. Hikma Pharmaceuticals PLC
- 14.7. Unique Pharmaceuticals Limited
- 14.8. Cipla Inc.
- 14.9. Viatris Inc.
- 14.10.Aurobindo Pharma
15. Strategic Recommendations
16. About Us & Disclaimer
